Endonovo Therapeutics stock analysis
Want to see ENDV full AI Analyst Report?
Endonovo Therapeutics (ENDV) Stock Price & Analysis
ENDV Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- N/A
- Previous Close
- $0.01
- Volume
- N/A
- Average Volume (3M)
- 92.65K
- Market Cap
- $180.76K
- Enterprise Value
- $6.93T
- Total Cash (Recent Filing)
- $13.68K
- Total Debt (Recent Filing)
- $7.09M
- Price to Earnings (P/E)
- ―
- Beta
- 280.11
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Innovative Product Offering
Endonovo's focus on non-invasive, bioelectronic therapies positions it well in the growing field of regenerative medicine, offering a unique solution for pain management and recovery.
Revenue Model Diversity
A diverse revenue model including sales, leases, and partnerships enhances revenue stability and potential growth through multiple streams.
Cash Flow Improvement
Improvement in free cash flow indicates better cash management, which is crucial for sustaining operations and funding future growth initiatives.
Bears Say
Financial Instability
Negative equity and high liabilities indicate financial distress, posing risks to long-term viability and limiting strategic options.
Revenue Decline
Inconsistent revenue trends undermine financial stability and growth prospects, challenging the company's ability to sustain operations.
Profitability Challenges
Negative margins highlight operational inefficiencies and cost management issues, impacting the company's ability to achieve profitability.
ENDV FAQ
What is Endonovo Therapeutics’s market cap?
When is Endonovo Therapeutics’s upcoming earnings report date?
How were Endonovo Therapeutics’s earnings last quarter?
Is Endonovo Therapeutics overvalued?
Does Endonovo Therapeutics pay dividends?
What is Endonovo Therapeutics’s EPS estimate?
How many shares outstanding does Endonovo Therapeutics have?
What happened to Endonovo Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Endonovo Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Endonovo Therapeutics
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alan Brian Collier
- Employees
- 1
- Website
- www.endonovo.com
- Address
- 6320 Canoga Avenue, Woodland Hills, CA, 91367, US

